Stephen Thompson

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition

Susan Wyllie, Stephen Brand, Michael G. Thomas et al. · Proceedings of the National Academy of Sciences · 2019 · 173 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Abnormally-fucosylated serum haptoglobins in patients with inflammatory joint disease

Stephen Thompson, Carol Kelly, I D Griffiths et al. · Clinica Chimica Acta · 1989 · 51 citations

Medicine, Clinical Sciences, Internal Medicine +12

Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis

Michael G. Thomas, Manu De Rycker, Myriam Ajakane et al. · Journal of Medicinal Chemistry · 2018 · 49 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against <i>Trypanosoma cruzi</i>

Stephen Brand, Eun Jung Ko, Elisabet Viayna et al. · Journal of Medicinal Chemistry · 2017 · 44 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis

Michael G. Thomas, Stephen Brand, Manu De Rycker et al. · Journal of Medicinal Chemistry · 2021 · 39 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13